October 28, 2022

Zhaoke Ophthalmology’s Partner Vyluma Announces Positive Results from Phase III CHAMP Study of NVK002 for Treatment of Myopia Progression in Children

HONG KONG, Oct 28, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical…

August 24, 2022

Zhaoke Ophthalmology Announces 2022 Interim Results

HONG KONG, Aug 24, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or the “Company”, SEHK: 6622), a leading ophthalmic pharmaceutical…

August 3, 2022

Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002

HONG KONG, Aug 3, 2022 – (ACN Newswire via SEAPRWire.com) – Zhaoke Ophthalmology Limited (“Zhaoke Ophthalmology” or “the Company”, SEHK: 6622), a leading ophthalmic pharmaceutical…

November 12, 2020

Zhaoke Ophthalmology Announced First Patient Completes Three Year Enrollment in Phase III CHAMP Study of NVK-002

HONG KONG, Nov 12, 2020 – (ACN Newswire) – Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. (“Zhaoke Hong Kong”) is pleased to announce today that the…